Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

The Phase 1 trial is funded through Project NextGen, a U.S. government agency initiative to develop next-generation COVID-19 vaccines and therapeutics through public-private partnerships. The trial ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Covid-19 is now ubiquitous – but hospitalisations ... we still need better therapeutics and vaccines, for some people at least in the future." For essential climate news and hopeful developments ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

“I’m not convinced that Covid-19 human challenge models turned out to be critical to the effort to develop biologics, vaccines and therapeutics,” Lyke wrote in her email. Chiu ...